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Abstract
Background: Overall survival after chemo-radiotherapy (CRT) for head and neck cancer ranges between 50 and
60% after 5 year of follow-up. Local and/or regional recurrence is the most frequent form of therapy failure. The
aim of this study is to investigate whether the initial location and size change of pathological lymph nodes as
evaluated on Computed Tomography (CT) studies can help predict outcome.
Methods: One hundred eighty-three patients with lymph node-positive head and neck cancer were treated with
radiotherapy (RT) or CRT. CT studies pre- and post-treatment were reviewed for lymph node size and location.
Data were correlated with local control, regional control, metastasis free survival, disease free survival and overall survival.
Results: Regarding the risk for distant metastasis, a significant influence was seen for the location of the
pathological lymph nodes. The metastatic risk increases when levels IV-V are affected rather than levels I-III.
A similar observation is seen for levels VI-VII. Regional control improves with decreasing lymph node diameter
and volume as evaluated on CT.
Conclusions: Both location and size change of pathological lymph nodes are of prognostic value after CRT for
head and neck cancer.
Keywords: Cancer of the head and neck, Computed tomography, Neoplasm recurrence locoregional,
Radiotherapy, Lymph nodes
Background
Head and neck cancer encompasses a large number of
tumor entities originating from subsites such as the
nasal cavity, nasopharynx, oral cavity, oropharynx,
larynx, hypopharynx and salivary glands. The majority
of these tumors are squamous cell carcinoma [1]. Head
and neck cancer is the fifth most common cancer
worldwide. In the United States about 55,070 new
cases were estimated for the year 2014 [2].
Approximately 60 to 80% of patients present with
locoregionally advanced disease at time of diagnosis.
Concurrent radiation therapy (RT) and chemotherapy
has become the standard of care for this subset of pa-
tients [3, 4]. Overall survival after chemo-radiotherapy
(CRT) ranges between 50 and 60% after 5 year of follow
up. Local and/or regional recurrence is the most fre-
quent form of therapy failure after CRT, while failure
due to metastasis is much less common [5–7]. Close
follow-up of the neck after CRT in this patient group is
therefore very important. There is a wide variability re-
garding the decision for salvage neck dissection as well
as post-treatment surveillance imaging.
The aim of this retrospective study is to investigate
whether the initial location of the pathological lymph
nodes and size changes after treatment evaluated using
CT studies, in patients diagnosed with a locoregionally
advanced invasive head and neck squamous cell carcin-
oma, can help predict outcome and can help us in
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selecting patients who might benefit from a closer
follow-up with more frequent radiological examinations.
Methods
Patients
Between January 2002 and December 2012, 539
patients with invasive head and neck squamous cell car-
cinoma were treated with (C)RT at our centre. After
the exclusion of patients with in situ cancer, metasta-
sized disease or N0 disease at time of diagnosis,
unknown primary tumors, nasopharyngeal or sinonasal
primaries, RT at another centre and neoadjuvant
chemotherapy or upfront surgery before RT, we had a
cohort of 183 patients for further analysis. Of these pa-
tients 183 patients, 168 had a CT evaluation 4 months
following the end of treatment.
All patients received external beam radiotherapy and
were CT planned. The primary tumor and pathological
lymph nodes were irradiated to doses ranging from
69.96 to 72 Gy. Mean overall treatment time was
43.4 days (range, 37-58 days). Most patients received
concurrent cisplatin. A smaller group was treated with
cetuximab or carboplatin/5-fluoro-uracil, or was in-
cluded in a clinical trial and received alternative or
additional therapeutic regimens. Patient and treatment
characteristics are presented into more detail in
Table 1. For all patients with oropharyngeal tumors,
formalin-fixed, paraffin-embedded tissue was central-
ized (University Hospital of Leuven) for Human papilloma
virus (HPV)-status determination. HPV testing was per-
formed using a previously validated algorithm using p16
immunohistochemistry followed by HPV-polymerase
chain reaction (PCR). A tumor was regarded as HPV re-
lated when both p16 immunohistochemistry as well as
HPV-PCR were positive. For p16 immunohistochemistry
a purified mouse anti-human p16 antibody (G175-405,
BD Pharmigen) was used. Sections were scored as p16
positive when clear p16 immunoreactivity was seen in at
least 50% of cells.
CT studies were carried out before treatment and
4 months after the completion of treatment. If the CT
scan was negative at 4 months, further follow-up was
done by clinical examination. PET-CT examination was
not routinely performed in the patients.
Analysis of the CT imaging data
CT-scans prior and following CRT were reviewed for all
included patients. All CT studies were performed using
multidetector spiral CT. An iodinated contrast agent
was injected in most patients; 100 ml at a rate of 1-
1.5 ml/s. Scanning was started 80-100 s after the start of
the contrast agent injection. The native CT-images were
acquired with a slice thickness of 0.6-0.75 mm, and re-
formatted for display with a slice thickness of 3 mm.
To obtain volumes and diameters of the lymph nodes,
every lymph node was contoured on each slide. Con-
secutively, volumes and diameters were calculated using
the Impax Volume Viewing 3D software from Agfa
Healthcare. At patient level volumes were obtained by
considering the sum of all pathological lymph nodes vol-
umes in one patient. At nodal level individual patho-
logical lymph nodes volumes were used. Lymph node
levels were clustered (level I-III, IV-V and VI-VII) and
Table 1 Patient and Treatment Characteristics
Characteristic No. of patients (n = 183) %





































cisplatin + tirapazamine 8 4
cisplatin + zalutumumab 1 1
Abbreviations: 3D CRT three-dimensional conformal radiation therapy, IMRT
intensity-modulated radiation therapy, 5-FU 5-fluoro-uracil, HPV Human papilloma
virus. a1 patient had 4 synchronous head and neck malignancies and was not
included in the T-classification statistics
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compared pairwise. Furthermore, necrosis, calcifications
and ECS was evaluated on all the CT studies. CT criteria
for ECS were apparent fat and soft tissue infiltration or
infiltration of sternocleidomastoid muscle, internal jugu-
lar vein or carotid artery.
All CT scans were analyzed by a single observer (a
professor in radiology specialized in head and neck im-
aging) concerning the presence of pathological lymph
nodes, the level of the lymph nodes, and the presence of
extracapsular spread or necrosis. The volume and diam-
eter of the lymph nodes were measured by a resident in
radiation oncology under the supervision of a radiologist
and radiation oncologist specialized in head and neck
cancer.
Statistical analysis
Description of the time-to-event outcome (LC (local
control), RC (regional control), MFS (metastasis free
survival), DFS (disease free survival), OS (overall sur-
vival)) of the patient cohort was based on Kaplan-Meier
estimates. The predictive power of localization and
volume changes were analyzed by Cox regression
models, and results presented as hazard ratios (HR)
with 95% confidence intervals. Predictors for binary
outcome were analyzed by logistic regression models,
and results presented as odds ratios (OR) with 95%
confidence intervals. Furthermore, a multivariate
analysis was done to correct for T stage, N stage,
pre-RT diameter, the presence of necrosis or calcifi-
cations within the pathological lymph nodes, HPV
and ECS.
Analyses at lymph node-level were based on general-
ized estimating equations (GEE) to account for clus-
tering of lymph nodes within patients. Size changes of
pathological lymph nodes are presented as percentage
of change. A negative % indicates decrease, a positive
% increase. Disappearing pathological lymph nodes
after treatment were considered as a 100% decrease of
volume and diameter. Analyses have been performed
using SAS software (version 9.4 of the SAS System for
Windows).
Volume change was analyzed at patient level as
well at individual nodal level. Data at patient level
were correlated with RC, MFS, DFS and OS, with
inclusion of disappearing pathological lymph nodes
(100% decrease of volume) after treatment. At indi-
vidual nodal level data were correlated with individ-
ual lymph node relapse (LNR), and analyzed both
with in- and exclusion of disappearing pathological
lymph nodes.
Change of largest axial diameter was analyzed on in-
dividual nodal level only, both with and without disap-
pearing pathological lymph nodes after treatment.
Results
Survival, disease control, CT characteristics
We report the following 2-year outcome rates: LC 86%
(95% Confidence Interval: 80-90%), RC 83% (95% Con-
fidence Interval: 77-88%), MFS 77% (95% Confidence
Interval: 70-83%), DFS 65% (95% Confidence Interval:
57-71%) and OS 70% (95% Confidence Interval: 63-
77%). Median observed follow-up was 5.04 years (Q1
3.48 years; Q3 7.04 years). For 116 patients we had at
least 2 years of follow-up.
The pre- and post-CT study characteristics are pre-
sented in Table 2 a and b.
Location
The distribution of affected lymph node levels in our
patient cohort is presented in Fig. 1. Level II was most
frequently affected. Regarding the risk for distant me-
tastasis, a significant influence was seen for the location
of the pathological lymph nodes. The metastatic risk in-
creases when levels IV-V are affected rather than levels
I-III. A similar observation is seen for levels VI-VII
(Table 3). On the other hand, no significant differences
were found for RC or DFS.
Size change
Volume
At a patient level, following multivariate analysis, less
decrease of total lymph node volume on a CT study was
significantly associated with a higher risk for regional re-
lapse (OR 1.039, p = 0.003), distant metastasis (HR 1.006,
p = 0.0277) and poorer DFS (HR 1.01, p = <0.001) and
OS (HR 1.006, p = 0.0037). At nodal level, less decrease
of volume of an individual lymph node was associated
with a higher risk for LNR, both with in- (OR 1.015, p =
0.0126) and exclusion (OR 1.009, p = 0.033) of com-
pletely resoluting pathological lymph nodes.
Largest axial diameter
Less decrease of largest axial diameter or an increase of
diameter was correlated with a higher risk for LNR. Both
with and without considering completely resoluting
pathological lymph nodes, a nonlinear trend was ob-
served for this relation (Figs. 2 and 3). Hence, the OR
associated with a 1% increase in diameter around the
median value was conducted (Table 4).
Discussion
In an era where the role of planned neck dissection after
CRT for locoregionally advanced head and neck cancer
is diminishing [8–10], using prognostic information de-
rived from the clinic and radiological examinations
which can help predict treatment outcome and thereby
the necessity of neck dissection, is gaining importance.
The goal of this study is to situate the prognostic value
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of the location of pathological lymph nodes, as well as
size change of pathological lymph nodes as evaluated
on CT studies in the follow up after (C)RT. Data were
conducted from a large patient cohort treated at our in-
stitute with (C)RT but without adjuvant neck dissec-
tion. As a result of this, data were correlated with
clinical outcome, and not with pathology results from
neck dissection. Therefore, we made sure to have suffi-
cient follow-up for every patient. Multivariate analysis
were done to correct for T stage, N stage, pre-RT diam-
eter, necrosis, calcifications, HPV and ECS, since these
factors are known to impact outcome [11–16].
To investigate the prognostic impact of the location of
pathological lymph nodes, we analyzed the distribution
of affected lymph node levels in our patient cohort, clus-
tered adjacent levels and compared them to each other.
As described for overall survival by Jones et al. in a large
cohort of 947 patients, one would expect a worse prog-
nosis with pathological involvement of higher numerical
lymph node levels [11]. We could establish a significant
correlation between location and metastatic risk, without
significant impact on the DFS. Involvement of level IV-V
entails a higher risk to develop metastasis compared to
level I-III. A similar, correlation was seen for involve-
ment of level VI-VII compared to level IV-V; with a
higher risk metastatic for involvement of level VI-VII.
Presence of retropharyngeal lymph node metastasis
(level VII), is known to be a risk factor for both regional
















No n/N (%) 146/183 (79.78%)
Yes n/N (%) 37/183 (20.22%)
Necrosis
No n/N (%) 60/183 (32.79%)
Yes n/N (%) 123/183 (67.21%)
Calcifications
No n/N (%) 180/183 (98.36%)















No n/N (%) 150/168 (89.29%)
Yes n/N (%) 18/168 (10.71%)
Necrosis
No n/N (%) 115/168 (68.45%)
Yes n/N (%) 53/168 (31.55%)
Calcifications
No n/N (%) 147/168 (87.50%)
Yes n/N (%) 21/168 (12.50%)
Fig. 1 Distribution of affected lymph node levels
Table 3 Impact of PLN localization on metastatic risk








I-III IV-V 0.325 (0.165;0.639) 0.0011 0.0002
IV-V VI-VII 0.461 (0.127;0.745) 0.0852 0.0302
Hazard Ratio <1 (>1) means lower (higher) risk for lower levels
Abbreviations: CI confidence interval, PLN pathological lymph node. aCorrected
for T stage, N stage, pre-radiotherapy diameter, necrosis, calcifications, extra-
capsular spread and HPV
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and distant recurrence [12–15]. We could validate this
result in our patient group for distant recurrence. Based
on our data, and previous publications on this subject,
we can state that involvement of higher numerical
lymph node levels as evaluated on CT studies pretreat-
ment entails a higher metastatic risk and represents
more aggressive and advanced disease.
A second goal was to investigate the prognostic value
of size change as evaluated on CT studies of pathological
lymph nodes after (C)RT (radiotherapy with or without
chemotherapy). Therefore we considered both volume
and largest axial diameter change. The latter only at in-
dividual nodal level, given the fact that after treatment,
determination of the largest axial diameter does not
necessarily involve the same lymph node. Volume
change was both at patient and individual nodal level of
significant prognostic value. The less pronounced the
volume reduction, the poorer the RC, DFS, MFS, OS
and, at individual nodal level, and the more LNR. Due
to linear relationships between volume change and out-
come no clinically useful cut-off values could be
selected.
At individual nodal level the analysis was done both
in- and excluding completely responding lymph nodes.
Including these lymph nodes yields a theoretical predict-
ive prognostic effect of size change of pathological
lymph nodes after treatment. Excluding them delivers us
more clinically useful information about the predictive
Fig. 2 Nonlinear trend of diameter change in relation with risk of Lymph Node Relapse (LN Relapse) with inclusion of completely responding
LN’s. The dots represent predictions for individual LN’s
Fig. 3 Nonlinear trend of diameter change of diameter change in relation with risk of Lymph Node Relapse (LN Relapse) with exclusion of
completely responding LN’s. The dots represent predictions for individual LN’s
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effect of the size change of a residual lymph node after
treatment. In the clinic, disappeared pathological lymph
nodes on post-treatment CT is considered obviously as a
favorable prognostic sign. However, even after excluding
disappearing pathological lymph nodes, the relationship
between volume change and LNR remained significant.
Our results are in concordance with the data published
by Clavel et al. In patients with node-positive head and
neck cancer, a significant effect of volume change after
CRT was reported [16]. In the light of adaptive RT, vol-
ume change of tumor and pathological lymph nodes
during treatment has been studied extensively. However,
data on the prognostic value of volume change after but
also during RT are scarce. Mishra et al. failed to find a
correlation between nodal volume change during (C)RT
and neck control in 38 patients with locoregionally
advanced head and neck cancer [17]. Besides volume
change, also the impact of change of largest nodal axial
diameter on LNR was considered. Our data revealed,
both in- and excluding completely responding patho-
logical lymph nodes, a significant correlation between
diameter change and outcome.
Because of this linear relationship no cut-off value
could be selected. Clavel et al. described a negative pre-
dictive value (NPV) of 100% for a diameter decrease
of > 80%. Hamilton et al. and Ojiri et al. proposed a cut-
off value of >50% with NPV’s of 94 and 100% respect-
ively [16, 18, 19]. An extensive discussion of the role of
other imaging modalities of the neck after (C)RT such
as ultrasound, PET-CT, and MRI is beyond the scope of
this article, but each of those are believed to be useful
in assessing response and the need for salvage neck dis-
section. Ultrasound (US), in combination with fine nee-
dle aspiration cytology (FNAC), is an inexpensive and
readily available tool. Yom et al. described a NPV of
95% for US-FNAC in the non-irradiated neck [20, 21].
Diagnostic efficacy and in particular NPV of FNAC for
residual or recurrent cervical lymph node metastasis is
however significantly reduced after previous RT [22].
Data on the role of post-treatment PET-CT are emer-
ging rapidly, and results are promising. Loo et al. de-
scribed a NPV of 100% for PET-CT obtained 3 months
after completion of radiotherapy [23]. This was further
investigated in a multi-center study (PET-NECK),
which recruited 564 patients with N2 or N3 head and
neck cancer treated with CRT and randomized between
routine ND and a wait and see approach if PET-CT 9-
13 weeks after treatment shows no abnormal FDGup-
take in the neck [24]. This study reports similar results
in patients who underwent PET-CT-guided surveillance
and those who underwent planned neck dissection, but
surveillance resulted in fewer operations and was more
cost-effective. In the last few years advances in MRI,
with development of diffusion weighted MR (DW-MRI)
and dynamic contrast-enhanced MRI, have provided
additional information. Recently, Vandecaveye et al.
evaluated response after RT in 29 patients with DW-
MRI at three weeks after completion of treatment. He
reported a NPV of 96% for adenopathies per neck side,
and a sensitivity of 78% of DW-MRI versus 67% for
conventional MRI for detecting sub centimeter lymph
node metastasis [25].
This was a monocentric retrospective study, with its
inherent limitations, analyzing a heterogeneous pa-
tient population over a large period of time. Neverthe-
less, the strength of this study lies in the large number
of analyzed data and the fact that all measurements on
the CT scans were performed by the same observer,
with cooperation of both a radiation oncologist and
radiologist specialized in head and neck cancer. More-
over, sufficient follow-up was carried out in a uniform
manner.
Conclusions
Our data show the prognostic value of both location as
well as size change of pathological lymph nodes after
(C)RT in locoregionally advanced head and neck cancer.
Involvement of level VI-VII entails the highest meta-
static risk. In the follow-up of patients with lymph node
involvement of level VI-VII, the threshold to do radio-
logical examinations should be lower.
The less decrease of lymph node volume and largest
axial diameter after treatment, the worse the outcome.
Patients with less decrease in volume and largest axial
diameter as evaluated on the post-treatment CT scan
might therefore benefit from a more closer radiological
and clinical follow-up of the neck.
Table 4 Predictive value of diameter change for lymph node relapse
Dmax Odds ratio (95% CI) p-value*
with CR PLN ΔDmax (nonlinear trend) <0.001
ΔDmax (+1% ~median) 1.012 (1.006;1.017) <0.001
without CR PLN ΔDmax (nonlinear trend) 0.0167
ΔDmax (+1% ~median) 1.009 (1.003;1.015) 0.0062
OR > (<1) means higher (lower) risk for higher % of change
Abbreviations: LNR lymph node relapse, CR PLN completely resoluting pathological lymph node, ΔDmax change in largest axial diameter, CI confidence interval.
*Corrected for, pre-radiotherapy diameter, necrosis, calcifications and extra-capsular spread
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